| human | Q5 |
| P496 | ORCID iD | 0000-0003-0554-9943 |
| P106 | occupation | researcher | Q1650915 |
| P5008 | on focus list of Wikimedia project | WikiProject COVID-19 | Q87748614 |
| Q125416829 | |
| Q96341884 | A compendium answering 150 questions on COVID-19 and SARS-CoV-2 |
| Q47218672 | A fluorescent probe to unravel functional features of cannabinoid receptor CB1 in human blood and tonsil immune system cells |
| Q51543765 | A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy. |
| Q95279709 | A novel proangiogenic B cell subset is increased in cancer and chronic inflammation |
| Q91822382 | A novel whole blood gene expression signature for asthma, dermatitis and rhinitis multimorbidity in children and adolescents |
| Q96690282 | ARIA-EAACI statement on Asthma and COVID-19 (June 2, 2020) |
| Q104619239 | ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines - an EAACI-ARIA position paper |
| Q61703521 | Absence of T-regulatory cell expression and function in atopic dermatitis skin |
| Q100391845 | Advances and Recent Developments in Asthma in 2020 |
| Q47754954 | Advances and highlights in allergen immunotherapy: On the way to sustained clinical and immunologic tolerance |
| Q38391526 | Advances in allergen immunotherapy: aiming for complete tolerance to allergens |
| Q36150445 | Advances in allergen-specific immunotherapy |
| Q88268566 | Anionic surfactants and commercial detergents decrease tight junction barrier integrity in human keratinocytes |
| Q42484374 | Apoptosis and loss of adhesion of bronchial epithelial cells in asthma |
| Q35931532 | Apoptosis in tissue inflammation and allergic disease |
| Q36178094 | Are regulatory T cells the target of venom immunotherapy? |
| Q64089344 | Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer |
| Q104510448 | B regulatory cells in allergy |
| Q92560403 | B-cell responses in allergen immunotherapy |
| Q36479034 | Bacillus Calmette-Guerin, Mycobacterium bovis, as an immunomodulator in atopic diseases |
| Q104066931 | Biology and dynamics of B cells in the context of IgE-mediated food allergy |
| Q57808001 | Chronic rhinosinusitis: pathogenesis, therapy options, and more |
| Q39533734 | Claudin-1 expression in airway smooth muscle exacerbates airway remodeling in asthmatic subjects |
| Q46323321 | Clinical and immunologic effects of H1 antihistamine preventive medication during honeybee venom immunotherapy |
| Q96308112 | Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status |
| Q97543571 | Clinical, radiological and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients |
| Q80511609 | Comparison of Der p1-specific antibody levels in children with allergic airway disease and healthy controls |
| Q93197010 | Comparison of regulatory B cells in asthma and allergic rhinitis |
| Q36396910 | Computational analysis of multimorbidity between asthma, eczema and rhinitis |
| Q96158875 | Considerations on Biologicals for Patients with allergic disease in times of the COVID-19 pandemic: an EAACI Statement |
| Q48027078 | CpG-DNA enhances the tight junction integrity of the bronchial epithelial cell barrier |
| Q56827917 | Cytokine and Antibody Responses in Birch-Pollen-Allergic Patients Treated with Genetically Modified Derivatives of the Major Birch Pollen Allergen Bet v 1 |
| Q93369186 | Der p 1-specific regulatory T-cell response during house dust mite allergen immunotherapy |
| Q59354433 | Development and characterization of DNAzyme candidates demonstrating significant efficiency against human rhinoviruses |
| Q36525105 | Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report |
| Q95277436 | EAACI Allergen Immunotherapy User's Guide |
| Q96138249 | EAACI Biologicals Guidelines - Recommendations for severe asthma |
| Q59304047 | EAACI International Severe Asthma Forum (ISAF 2012) Gothenburg, Sweden. 11-13 October 2012. Abstracts |
| Q52739186 | Early suppression of basophil activation during allergen-specific immunotherapy by histamine receptor 2. |
| Q97638459 | Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI Biologicals Guidelines |
| Q89739188 | Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma |
| Q89605999 | Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma |
| Q90185425 | Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma |
| Q98242929 | Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria - a systematic review for the EAACI Biologicals Guidelines |
| Q96164919 | Environmental factors in epithelial barrier dysfunction |
| Q42331374 | Erratum to: Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement |
| Q39011616 | Exposure to nonmicrobial N-glycolylneuraminic acid protects farmers' children against airway inflammation and colitis |
| Q51996007 | Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. |
| Q41918189 | Guidelines for the use of flow cytometry and cell sorting in immunological studies |
| Q90841989 | Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition) |
| Q93206312 | Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement |
| Q36615443 | Healthy immune response to allergens: T regulatory cells and more |
| Q91419833 | Highlights of Novel Vaccination Strategies in Allergen Immunotherapy |
| Q46496199 | Histamine receptor H1 signaling on dendritic cells plays a key role in the IFN-γ/IL-17 balance in T cell-mediated skin inflammation |
| Q125406456 | How does global warming contribute to disorders originating from an impaired epithelial barrier? |
| Q49913897 | Human CD40 ligand-expressing type 3 innate lymphoid cells induce IL-10-producing immature transitional regulatory B cells |
| Q51725629 | Human NK1 and NK2 subsets determined by purification of IFN-gamma-secreting and IFN-gamma-nonsecreting NK cells. |
| Q92534211 | Human type 2 innate lymphoid cells disrupt skin keratinocyte tight junction barrier by IL-13 |
| Q43822962 | IL-10 controls Aspergillus fumigatus- and Pseudomonas aeruginosa-specific T-cell response in cystic fibrosis |
| Q57265326 | IL-10 inhibits CD28 and ICOS costimulations of T cells via src homology 2 domain—containing protein tyrosine phosphatase 1 |
| Q46295443 | IL-10 suppresses CD2-mediated T cell activation via SHP-1. |
| Q85347553 | IL-10-overexpressing B cells regulate innate and adaptive immune responses |
| Q57101706 | IL-32 is expressed by human primary keratinocytes and modulates keratinocyte apoptosis in atopic dermatitis |
| Q44429951 | IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy |
| Q50961409 | IgE class switching and cellular memory. |
| Q34330562 | IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses |
| Q91230645 | Il-10 producing T and B cells in allergy |
| Q34987280 | Immune regulation by histamine |
| Q94589127 | Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19 |
| Q34548321 | Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells |
| Q37584824 | Immune tolerance in allergy |
| Q125477745 | Immune-mediated disease caused by climate change-associated environmental hazards: mitigation and adaptation |
| Q37283772 | Immunologic responses to sublingual allergen immunotherapy. |
| Q96692386 | Immunology of COVID-19: mechanisms, clinical outcome, diagnostics and perspectives - a report of the European Academy of Allergy and Clinical Immunology (EAACI) |
| Q91569176 | Impact of high-altitude therapy on type-2 immune responses in asthma patients |
| Q44290592 | Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites |
| Q91584697 | Impaired memory B-cell development and antibody maturation with a skewing toward IgE in patients with STAT3 hyper-IgE syndrome |
| Q36979997 | In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure |
| Q51966464 | Increased activation-induced cell death of high IFN-gamma-producing T(H)1 cells as a mechanism of T(H)2 predominance in atopic diseases. |
| Q96350401 | Increased antiviral response in circulating lymphocytes from hypogammaglobulinemia patients |
| Q82334324 | Induction and maintenance of allergen-specific FOXP3+ Treg cells in human tonsils as potential first-line organs of oral tolerance |
| Q91223814 | Induction of human regulatory innate lymphoid cells from group 2 innate lymphoid cells by retinoic acid |
| Q102060037 | Influence of Innate Immunity on Immune Tolerance |
| Q52552152 | Inhibition of T helper 2-type responses, IgE production and eosinophilia by synthetic lipopeptides. |
| Q39396364 | Inhibition of angiogenesis by IL-32: possible role in asthma |
| Q38941705 | Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases. |
| Q34168692 | Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases. |
| Q38725460 | International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics |
| Q58616421 | Intralymphatic Immunotherapy: Update and Unmet Needs |
| Q57266970 | Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections |
| Q89997356 | Laundry detergents and detergent residue after rinsing directly disrupt tight junction barrier integrity in human bronchial epithelial cells |
| Q37434885 | Mechanisms and treatment of allergic disease in the big picture of regulatory T cells |
| Q38652627 | Mechanisms of Aeroallergen Immunotherapy: Subcutaneous Immunotherapy and Sublingual Immunotherapy |
| Q34263412 | Mechanisms of IFN-γ-induced apoptosis of human skin keratinocytes in patients with atopic dermatitis |
| Q91419819 | Mechanisms of Subcutaneous and Sublingual Aeroallergen Immunotherapy: What Is New? |
| Q59271653 | Mechanisms of allergen-specific immunotherapy |
| Q79828953 | Mechanisms of allergen-specific immunotherapy |
| Q81627764 | Mechanisms of allergen-specific immunotherapy |
| Q83143842 | Mechanisms of allergen-specific immunotherapy |
| Q99233243 | Mechanisms of allergen-specific immunotherapy and allergen tolerance |
| Q41196294 | Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens |
| Q38155063 | Mechanisms of allergen-specific immunotherapy and novel ways for vaccine development |
| Q89390588 | Mechanisms of allergen-specific immunotherapy: Diverse mechanisms of immune tolerance to allergens |
| Q36478997 | Mechanisms of allergen-specific immunotherapy: T-regulatory cells and more. |
| Q38192151 | Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens |
| Q39402881 | Mechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells. |
| Q36429815 | Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells |
| Q83703081 | Mechanisms of immune tolerance to allergens |
| Q37453510 | Mechanisms of immune tolerance to allergens in children |
| Q35140130 | Mechanisms of immune tolerance to allergens: role of IL-10 and Tregs |
| Q37870449 | Mechanisms of subcutaneous allergen immunotherapy |
| Q30238498 | Mechanisms of the Development of Allergy (MeDALL): Introducing novel concepts in allergy phenotypes |
| Q49949791 | Modified Allergens for Immunotherapy |
| Q38233938 | Modulation of immune responses by immunotherapy in allergic diseases |
| Q37855941 | NK cell subsets and their role in allergy |
| Q38133054 | Natural killer cells in patients with allergic diseases |
| Q33846653 | Nature of regulatory T cells in the context of allergic disease |
| Q27016089 | New treatments for allergen immunotherapy |
| Q37728000 | Novel immunotherapeutic approaches for allergy and asthma |
| Q50189746 | Novel mechanisms in immune tolerance to allergens during natural allergen exposure and allergen-specific immunotherapy. |
| Q57919494 | Platelet-activating factor decreases skin keratinocyte tight junction barrier integrity |
| Q30884726 | Prebiotics, probiotics, synbiotics, and the immune system: experimental data and clinical evidence |
| Q91712548 | Precision/Personalized Medicine in Allergic Diseases and Asthma |
| Q46737041 | Prevention of allergy by a recombinant multi-allergen vaccine with reduced IgE binding and preserved T cell epitopes |
| Q61959821 | Regulation of Allergic Inflammation by T Cells and Cytokines in Atopic Dermatitis |
| Q82028854 | Regulation of T cells and cytokines by the interleukin-10 (IL-10)-family cytokines IL-19, IL-20, IL-22, IL-24 and IL-26 |
| Q39676675 | Regulation of bronchial epithelial barrier integrity by type 2 cytokines and histone deacetylases in asthmatic patients |
| Q37913659 | Regulation of the immune response and inflammation by histamine and histamine receptors |
| Q60958243 | Regulatory Immune Mechanisms in Tolerance to Food Allergy |
| Q80455086 | Regulatory NK cells suppress antigen-specific T cell responses |
| Q37273130 | Regulatory effects of histamine and histamine receptor expression in human allergic immune responses |
| Q122983094 | Rhinitis associated with asthma is distinct from rhinitis alone: The |
| Q59354094 | Rhinovirus Species-Specific Antibodies Differentially Reflect Clinical Outcomes in Health and Asthma |
| Q55452799 | Rhinovirus infection has allergen-specific tolerance-breaking effects on PBMCs of healthy individuals. |
| Q91897255 | Rhinovirus species and tonsillar immune responses |
| Q30371972 | Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement |
| Q102055955 | Risk factors for severe and critically ill COVID-19 patients: a review |
| Q90358169 | Role of Der p 1-specific B cells in immune tolerance during 2 years of house dust mite-specific immunotherapy |
| Q53740730 | Role of IgG4 in IgE-mediated allergic responses. |
| Q37606265 | Role of Regulatory Cells in Oral Tolerance |
| Q37690644 | Role of Treg in immune regulation of allergic diseases. |
| Q36303732 | Role of bacillus Calmette-Guérin as an immunomodulator for the prevention and treatment of allergy and asthma |
| Q38946824 | Role of regulatory B cells in immune tolerance to allergens and beyond. |
| Q38264806 | Scientific foundations of allergen-specific immunotherapy for allergic disease. |
| Q57069225 | Secreted IgD Amplifies Humoral T Helper 2 Cell Responses by Binding Basophils via Galectin-9 and CD44 |
| Q91547560 | Skin barrier damage after exposure to paraphenylenediamine |
| Q30485173 | Specific immunotherapy and turning off the T cell: how does it work? |
| Q88003627 | Staphylococcus aureus enhances the tight junction barrier integrity in healthy nasal tissue, but not in nasal polyps |
| Q77767898 | T cells and effector mechanisms in the pathogenesis of atopic dermatitis |
| Q28201095 | T cells and eosinophils cooperate in the induction of bronchial epithelial cell apoptosis in asthma |
| Q52007602 | T helper (Th) 2 predominance in atopic diseases is due to preferential apoptosis of circulating memory/effector Th1 cells. |
| Q36140975 | T regulatory cells and allergy. |
| Q36327399 | T regulatory cells in allergen-specific immunotherapy. |
| Q36342208 | T regulatory cells in allergy |
| Q35875954 | T regulatory cells in allergy and health: a question of allergen specificity and balance. |
| Q36308401 | T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases |
| Q43489644 | T-cell regulation during viral and nonviral asthma exacerbations |
| Q37762368 | T-cell response to allergens |
| Q36432855 | T-cell subsets in the pathogenesis of human asthma |
| Q38015504 | TH17 and TH22 cells: a confusion of antimicrobial response with tissue inflammation versus protection. |
| Q36897580 | TH17 cells in the big picture of immunology. |
| Q36150810 | Targets in allergy-directed immunotherapy. |
| Q42234103 | Th2-type cytokine-induced mucus metaplasia decreases susceptibility of human bronchial epithelium to rhinovirus infection. |
| Q38542576 | The Complex Type 2 Endotype in Allergy and Asthma: From Laboratory to Bedside |
| Q35620005 | The Induction of IL-33 in the Sinus Epithelium and Its Influence on T-Helper Cell Responses |
| Q91815015 | The Influence of Dietary Fatty Acids on Immune Responses |
| Q104473079 | The cannabinoid WIN55212-2 restores rhinovirus-induced epithelial barrier disruption |
| Q90799612 | The concepts of asthma endotypes and phenotypes to guide current and novel treatment strategies |
| Q125428030 | The epithelial barrier theory: Development and exacerbation of allergic and other chronic inflammatory diseases |
| Q60649414 | The expression of cannabinoid receptor 1 is significantly increased in atopic patients |
| Q36290094 | The relationship of serum vitamins A, D, E and LL-37 levels with allergic status, tonsillar virus detection and immune response |
| Q96614661 | The role of Treg cell subsets in allergic disease |
| Q92435887 | The use of biologics for immune modulation in allergic disease |
| Q37567423 | Therapeutic manipulation of immune tolerance in allergic disease |
| Q91866015 | Tight junction, mucin, and inflammasome-related molecules are differentially expressed in eosinophilic, mixed, and neutrophilic experimental asthma in mice |
| Q100408780 | Tolerance mechanisms in allergen immunotherapy |
| Q91409420 | Tolerance mechanisms of AIT |
| Q55347390 | Tonsillar cytokine expression between patients with tonsillar hypertrophy and recurrent tonsillitis. |
| Q100515460 | Trained immunity and tolerance in innate lymphoid cells, monocytes, and dendritic cells during allergen-specific immunotherapy |
| Q33591090 | Transcription factors RUNX1 and RUNX3 in the induction and suppressive function of Foxp3+ inducible regulatory T cells |
| Q90388262 | Transfer and loss of allergen-specific responses via stem cell transplantation: a prospective observational study |
| Q85782136 | Triggering of specific Toll-like receptors and proinflammatory cytokines breaks allergen-specific T-cell tolerance in human tonsils and peripheral blood |
| Q38845471 | Type 2 innate lymphoid cells disrupt bronchial epithelial barrier integrity by targeting tight junctions through IL-13 in asthmatic patients |
| Q45347003 | Under the skin or under the tongue: differences and similarities in mechanisms of sublingual and subcutaneous immunotherapy |
| Q37990222 | Understanding the complexity of IgE-related phenotypes from childhood to young adulthood: a Mechanisms of the Development of Allergy (MeDALL) seminar |
| Q41273420 | Update in the mechanisms of allergen-specific immunotheraphy |
| Q120070390 | Vaccines and allergic reactions: The past, the current COVID‐19 pandemic, and future perspectives |
| Q47106906 | WAO International Scientific Conference (WISC 2016) Abstracts: Jerusalem, Israel. 6–9 December 2016. |
| Q28185664 | A second step of chemotaxis after transendothelial migration: keratinocytes undergoing apoptosis release IFN-gamma-inducible protein 10, monokine induced by IFN-gamma, and IFN-gamma-inducible alpha-chemoattractant for T cell chemotaxis toward epider |
Search more.